Dengue Fever - Pipeline Insight, 2024

This “Dengue Fever - Pipeline Insight, 2024” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Dengue Fever pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Dengue Fever: Understanding

Dengue Fever: Overview

Dengue fever is a mosquito-borne viral infection caused by the dengue virus, which is transmitted primarily by Aedes aegypti mosquitoes. It is prevalent in tropical and subtropical regions around the world, especially in Southeast Asia, the Pacific Islands, the Caribbean, and Central and South America. The disease presents with a sudden onset of high fever, severe headache, pain behind the eyes, joint and muscle pain, rash, and mild bleeding manifestations such as nose or gum bleeding or easy bruising. Symptoms typically appear 4-10 days after the mosquito bite and can last for 2-7 days.

Common symptoms generally last for 2 to 7 days and can include: sudden, high fever (up to 106°F or 41°C), severe headache, swollen lymph glands, severe joint and muscle pains, skin rash (appearing between 2 and 5 days after the initial fever). Symptoms of severe dengue can include: belly pain and tenderness, mild to severe vomiting (three times in 24 hours), mild bleeding from the nose or gums, vomiting blood or blood in stool, fatigue, restlessness, or irritability.

The exact course of events following the dermal injection of the dengue virus by a mosquito bite is unclear. Skin macrophages and dendritic cells appear to be the first targets. It is thought that the infected cells then move to the lymph nodes and spread through the lymphatic system to other organs. Viremia may be present for 24 to 48 hours before the onset of symptoms. A complex interaction of host and viral factors then occurs and determines whether the infection will be asymptomatic, typical, or severe. Severe dengue fever with increased microvascular permeability and shock syndrome is thought to be associated with infection due to a second dengue virus serotype and the patient's immune response.

Common laboratory findings include thrombocytopenia, leukopenia, elevated aspartate aminotransferase. The virus antigen is detectable by ELISA, polymerase chain reaction, or virus isolation from body fluids. Serology will reveal a marked increase in immunoglobulins. A confirmed diagnosis is established by culture, antigen detection, polymerase chain reaction, or serologic testing.

There is no specific treatment for dengue fever. Mild cases are managed with lots of fluids to prevent dehydration and getting plenty of rest. Pain relievers with acetaminophen can ease the headaches and pain associated with dengue fever. Pain relievers with aspirin or ibuprofen should be avoided. The first dengue vaccine, Dengvaxia® (CYD-TDV) developed by Sanofi Pasteur was licensed in December 2015 and has now been approved by regulatory authorities in ~20 countries.  

"Dengue Fever - Pipeline Insight, 2024" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Dengue Fever pipeline landscape is provided which includes the disease overview and Dengue Fever treatment guidelines. The assessment part of the report embraces, in depth Dengue Fever commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Dengue Fever collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlight

The companies and academics are working to assess challenges and seek opportunities that could influence Dengue Fever R&D. The therapies under development are focused on novel approaches to treat/improve Dengue Fever.

Dengue Fever Emerging Drugs Chapters

This segment of the Dengue Fever report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, II/III I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Dengue Fever Emerging Drugs

V181: Merck Sharp & Dohme LLC

V181 is an investigational quadrivalent dengue vaccine. V181 is a promising investigational dengue vaccine candidate developed by Merck & Co., aimed at providing immunity against dengue fever, a mosquito-borne viral infection that poses significant health risks worldwide, particularly in tropical and subtropical regions. V181 is based on a purified inactivated virus (PIV) technology. This approach is similar to that used in inactivated vaccines for other viruses, intending to create a strong immune response without causing infection. Early studies suggest that V181 elicits a broad and balanced immune response across all dengue virus types, aiming to provide comprehensive protection and potentially prevent severe outcomes like dengue hemorrhagic fever. Currently the drug is in Phase II stage of its development for the study of Dengue fever.

naNO-dengue: Emergex Vaccines Holding

naNO-DENGUE, a vaccine candidate by Emergex, is specifically designed to target dengue virus infections, which are transmitted by Aedes mosquitoes and represent a major global health threat. The vaccine is composed of nanoparticles that deliver synthetic viral peptides to the immune system. These peptides are fragments of the dengue virus proteins engineered to stimulate a robust T-cell response against infected cells without using live or inactivated viruses. This T-cell-focused approach may bypass some of the challenges associated with traditional dengue vaccines, such as ADE, which can exacerbate infection severity upon subsequent dengue exposures. Currently the drug is in Phase I stage of its development for the study of Dengue fever.

Dengue Fever: Therapeutic Assessment

This segment of the report provides insights about the different Dengue Fever drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Dengue Fever

There are approx. 10+ key companies which are developing the therapies for Dengue Fever. The companies which have their Dengue Fever drug candidates in the most advanced stage, i.e. Phase II include, Merck Sharp & Dohme LLC.

Phases

The report covers around 12+ products under different phases of clinical development like:

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of:
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Dengue Fever pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as:

• Monoclonal antibody
• Small molecule
• Peptide

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Dengue Fever: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Dengue Fever therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Dengue Fever drugs.

Dengue Fever Report Insights

• Dengue Fever Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Dengue Fever Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Dengue Fever drugs?
• How many Dengue Fever drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Dengue Fever?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Dengue Fever therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Dengue Fever and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Merck Sharp & Dohme LLC
• Emergex Vaccines Holding
• Novartis Pharmaceuticals
• Codagenix

Key Products

• V181
• naNO-dengue
• EYU688
• CDX DENV

This product will be delivered within 2 business days.